Safety and pharmacokinetics of the orally available antiprionic compound PRI‐002: A single and multiple ascending dose phase I study

Safety and pharmacokinetics of the orally available antiprionic compound PRI‐002: A single and multiple ascending dose phase I study

Abstract Introduction PRI‐002 is an orally available anti–amyloid beta (Aβ) prionic compound developed for direct disassembly of toxic Aβ oligomers relevant to Alzheimer's disease. Methods Two placebo‐controlled clinical phase I trials with oral dosing of PRI‐002 were conducted in healthy young...

Full description

Bibliographic Details
Main Authors: Janine Kutzsche, Dagmar Jürgens, Antje Willuweit, Knut Adermann, Carola Fuchs, Stefanie Simons, Manfred Windisch, Michael Hümpel, Wolfgang Rossberg, Michael Wolzt, Dieter Willbold
Format: Article
Language:English
Published: Wiley 2020-01-01
Series:Alzheimer’s & Dementia: Translational Research & Clinical Interventions
Subjects:
Alzheimer´s disease (AD)
anti‐Aβ‐prionic
first‐in‐human (FIH)
MAD
multiple ascending dose
pharmacokinetics
Online Access:https://doi.org/10.1002/trc2.12001

Internet

https://doi.org/10.1002/trc2.12001

Similar Items